 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: OCREVUS (ocrelizumab) |
|
***************************************************** |
|
#Post#: 3359-------------------------------------------------- |
|
(Abst.) Clinical outcomes of patients w/MS treated w/Ocrevus... |
|
By: agate Date: July 27, 2021, 7:01 pm |
|
--------------------------------------------------------- |
|
From PubMed (July 27, 2021)--"Clinical outcomes of patients with |
|
multiple sclerosis treated with ocrelizumab in a US community MS |
|
center: An observational study": |
|
https://pubmed.ncbi.nlm.nih.gov/34308352/ |
|
#Post#: 3389-------------------------------------------------- |
|
Ocrevus reduces MS relapse risk, but linked to more hospitalizat |
|
ions |
|
By: agate Date: August 26, 2021, 10:56 pm |
|
--------------------------------------------------------- |
|
An article about this study in Multiple Sclerosis News Today |
|
(August 25, 2021)--"Ocrevus reduces MS relapse risk, but linked |
|
to more hospitalizations": |
|
https://bit.ly/2WsvVA2 |
|
|
|
***************************************************** |
